----- Original Message -----
From: "Viner, Jane"
<[email protected]>
To: <
[email protected]>
Sent: Friday, October 06, 2006 5:16 PM
Subject: MHRA FOI request 06/321

> Dear Mr Medawar,
> Thank you for your request for information under the Freedom of
> Information Act.
> I confirm that work is currently underway on parts 1 and 2 of your
> request. However, I am contacting you in order to ensure that we fully
> understand the range of reports you are seeking in part 3 of your request.
> As you are aware, the Agency carries out a very large range of activities
> and, to enable us to deal with your request, we therefore would be
> grateful if you could define the range of activities for which you are
> seeking reports on.
> You are welcome to telephone me on 020 7084 2348 to discuss your request
> further.
> Yours sincerely,
> Jane Viner
> Head of Medicines Information and Web Services
> Medicines and Healthcare products Regulatory Agency

Reply: 09 October 2006: 09.42

  • Dear Ms Viner,

    FOI REQUEST 06/321

    Thank you for your 6 October email. I appreciate that the Agency is involved
    in a wide variety of activities and had attempted to limit my original
    request by specifying only ‘major’ reports. In the light of your query, I
    should now like to modify the original request.

    Please will you provide: [a] totals of expenditure by the Agency, in each of
    the years 2003 to 2006, on all significant reports and/or evaluations
    relating to the Agency activities specified below, commissioned by the MHRA;
    and [b] the titles of all such reports/evaluations received, the identity of
    the individual(s) and/or organisations commissioned; and date (or expected
    date) of delivery. I should like to receive this information about reports
    primarily relating to:

            the image, or perceptions of, the MHRA (including its committee and
    advisory group functions)

            quality of service to customers and relationships with major
    stakeholders (including committees and advisory bodies)

            achieving Agency (including its committee and advisory group
    functions) transparency and accountability

            the need to promote useful drug innovation and product development

            proposed and/or effected regulatory action for established
    medicinal products where the risk-benefit profile has changed significantly

            development of Agency (including its committee and advisory group
    functions) work relating to pharmacovigilance

            research directly relating to risks and benefits of specific
    products and medicines generally

            the MHRA’s role as competent authority for human blood and blood

            research relating to provision of drug information to end users of

            research relating to patient reporting of suspected adverse drug
    reactions; and

            other research directly related to safeguarding public health

    I hope this seems manageable, but you are welcome to telephone me on 020
    7586 7771 if you would like to discuss this request further.


    Charles Medawar